enVVeno Medical Corporation (NVNO)
NASDAQ: NVNO · Real-Time Price · USD
10.75
-0.49 (-4.36%)
At close: Aug 28, 2026, 4:00 PM EDT
10.70
-0.05 (-0.47%)
After-hours: Aug 28, 2026, 7:30 PM EDT
enVVeno Medical Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
33
Market Cap
7.34M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Trinity Biotech | 43.79M |
| WORK Medical Technology Group LTD | 10.72M |
| Biomerica | 4.33M |
| Intelligent Bio Solutions | 4.22M |
| IceCure Medical | 3.95M |
| VolitionRx | 2.46M |
| Sintx Technologies | 1.33M |
| Co-Diagnostics | 721.39K |
NVNO News
- 2 days ago - enVVeno Medical Participates in the Virtual Investor 'Why Now' On-Demand Conference - Accesswire
- 8 days ago - enVVeno Medical files $100M mixed securities shelf - TheFly
- 25 days ago - enVVeno announces publication of independent health economic study - TheFly
- 25 days ago - Independent Health Economic Study Recently Published in Journal of Vascular Surgery Reports Economic Dominance of enVVeno Medical's Replacement Venous Valve Therapy Compared to Standard of Care Treatments - Accesswire
- 4 weeks ago - enVVeno Medical reports Q2 EPS ($5.37) vs. ($11.52) last year - TheFly
- 4 weeks ago - enVVeno Medical sees cash runway into 3Q27 - TheFly
- 4 weeks ago - enVVeno Medical expects cash burn rate of $4M-$5M per quarter in 2H26 - TheFly
- 4 weeks ago - enVVeno Medical Reports Second Quarter 2026 Financial Results and Advances Towards FDA Pivotal Trial for First-in-Class Non-Surgical Replacement Venous Valve - Accesswire